Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 476 - 500 of 14342 in total

Vosoritide

Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans. It results from a gain-of-function missense mutation in FGFR3 that results in a dramatic suppression of bone growth, both in volume and in length.[A242273,A242277] Treatment for achondroplasia includes both surgical and pharmacological interventions, the...
Approved
Investigational
Matched Description: … Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans ... missense mutation in _FGFR3_ that results in a dramatic suppression of bone growth, both in volume and ... [A242273,A242277] Treatment for achondroplasia includes both surgical and pharmacological interventions …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Lutetium Lu 177 dotatate

A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as...
Approved
Investigational
Matched Description: … Targeting pancreas and other parts of the gastrointestinal tract such as the intestines and colon, neuroendocrine ... tumors may commonly metastasize to metastasize to the mesentery, peritoneum, and liver [A31697]. ... The presence of a radioligand allows monitoring of treatment response post therapy and prior to next …
Matched Categories: … Indicators and Reagents ... Somatostatin and Analogues ... Amino Acids, Peptides, and Proteins …

Tafasitamab

Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19...
Approved
Investigational
Matched Description: … results in the lysis of B-cells (both healthy and malignant). ... [L15302] It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains ... [L15292] Having previously received Breakthrough Therapy, Fast Track, and Orphan designations from …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Polistes annularis venom protein

Polistes annularis venom protein is an extract of Polistes annularis venom. Polistes annularis venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …

Sulfamerazine

A sulfanilamide that is used as an antibacterial agent.
Approved
Vet approved
Matched Categories: … Sulfonamides and trimethoprim ... sulfamerazine and trimethoprim ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Olaratumab

Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the...
Approved
Investigational
Matched Description: … It is composed of two heavy chain molecule fragments and 2 light chain fragments. ... binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and ... olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Triheptanoin

Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly.[A214812,A214817] Complications in lc-FAOD patients...
Approved
Investigational
Matched Description: … treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Pramlintide

Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
Approved
Investigational
Matched Description: … Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Asfotase alfa

Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). Hypophosphatasia is almost always fatal when severe skeletal disease is obvious at birth. By replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels...
Approved
Investigational
Matched Description: … morbidity and premature death. ... Food and Drug Administration (FDA) on October 23, 2015. ... 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved by …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Teclistamab

Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells. Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide bonds,[A253587, L43622] allowing the drug...
Approved
Investigational
Matched Description: … is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and ... [A253587] Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Alglucerase

Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated...
Approved
Investigational
Withdrawn
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Racephedrine

Approved
Experimental
Matched Categories: … Herbs and Natural Products ... Alpha-and Beta-adrenergic Agonists …

Ademetionine

Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)
Approved
Investigational
Nutraceutical
Matched Description: … Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all ... It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. …
Matched Categories: … Amino Acids and Derivatives ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Nucleic Acids, Nucleotides, and Nucleosides …

Pegademase

Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.
Approved
Matched Categories: … Enzymes and Coenzymes ... Antineoplastic and Immunomodulating Agents …

Lisocabtagene maraleucel

Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to brexucabtagene autoleucel and axicabtagene ciloleucel.[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has changed the treatment of B-cell lymphomas, significantly increasing survival rates over standard...
Approved
Matched Description: … maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and ... [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Tenofovir alafenamide

Tenofovir alafenamide is a novel tenofovir prodrug developed in order to improve renal safety when compared to the counterpart tenofovir disoproxil. Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal...
Approved
Matched Description: … group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and ... [L4388,L9010] Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval ... alafenamide is indicated to treat chronic hepatitis B,[L6241] treat HIV-1,[L4388,L6277,L6280,L6283] and …
Matched Categories: … Tenofovir and prodrugs ... Amino Acids, Peptides, and Proteins ... emtricitabine and tenofovir alafenamide ... emtricitabine, tenofovir alafenamide and rilpivirine ... emtricitabine, tenofovir alafenamide and bictegravir …

Technetium Tc-99m sulfur colloid

Technetium 99m sulfur colloid is a radiopharmaceutical diagnostic agent used in the evaluation of various conditions including lymph node metastases in breast cancer, detection of shunt patency, imaging of reticuloendothelial cells for assessment of liver function, and studies of esophageal transit and gastroesophageal reflux. Following injection or oral administration, single...
Approved
Investigational
Matched Description: … studies of esophageal transit and gastroesophageal reflux. ... detection of shunt patency, imaging of reticuloendothelial cells for assessment of liver function, and ... Depending on site of administration and intended usage, Technetium 99m sulfur colloid enters the capillaries …
Matched Categories: … Indicators and Reagents ... Hepatic and Reticulo Endothelial System ... Technetium (99Mtc), Particles and Colloids …

Semaglutide

Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection...
Approved
Investigational
Matched Description: … and reducing blood glucose. ... [A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. ... 1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Risankizumab

Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab...
Approved
Investigational
Matched Description: … [A254716] Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. ... It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …

Mosunetuzumab

Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody. It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as...
Approved
Investigational
Matched Description: … [L42230] It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 ... unlike CAR-T therapies such as [axicabtagene ciloleucel] and [tisagenlecleucel], it is an “off-the-shelf ... potential to circumvent resistance to [rituximab] in patients with follicular lymphoma,[A249320,L42230] and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Epoetin delta

Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
Approved
Investigational
Withdrawn
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Asparaginase Escherichia coli

Asparaginase derived from Escherichia coli (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from E. coli has clinically shown to exhibit antitumor...
Approved
Investigational
Matched Description: … enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and …
Matched Categories: … Enzymes and Coenzymes ... Antineoplastic and Immunomodulating Agents …

Obeticholic acid

Primary biliary cirrhosis, or PBC, is a progressive and chronic condition that leads to hepatic injury often resulting in end-stage liver failure that requires liver transplantation. Obeticholic acid is a farnesoid-X receptor (FXR) agonist used to treat this condition, possibly allowing for increased survival. In 2016, it was granted approval...
Approved
Matched Description: … Primary biliary cirrhosis, or PBC, is a progressive and chronic condition that leads to hepatic injury ... The NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected ... updated its prescribing information to contraindicate the use of obeticholic acid in patients with PBC and …
Matched Categories: … Bile Acids and Salts ... Bile and Liver Therapy ... Bile acids and derivatives ... Alimentary Tract and Metabolism …

Sulodexide

Sulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH).
Approved
Investigational
Matched Description: … Sulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …

Testosterone enantate benzilic acid hydrazone

Approved
Experimental
Matched Categories: … Testosterone and derivatives ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Displaying drugs 476 - 500 of 14342 in total